The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: Feasibility and acute toxicity

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 4, 2004, Pages 1056-1065

  Beckendorf, Véronique ^a   Guérif, Stéphane ^b   Le Prisé, Elisabeth ^c   Cosset, Jean Marc ^d   Lefloch, Olivier ^e   Chauvet, Bruno ^f   Salem, Naji ^g   Chapet, Olivier ^h   Bourdin, Sylvain ⁱ   Bachaud, Jean Marc ^j   Maingon, Philippe ^k   Lagrange, Jean Léon ^l   Malissard, Luc ^m   Simon, Jean Marc ⁿ   Pommier, Pascal ^o   Hay, Men H ^p   Dubray, Bernard ^q   Luporsi, Elisabeth ^a   Bey, Pierre ^d  

^a CENTRE ALEXIS VAUTRIN   (France)

^b University of Poitiers   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d INSTITUT CURIE   (France)

^e CHU BRETONNEAU   (France)

^f INSTITUT SAINTE CATHERINE   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h HOSPICES CIVILS DE LYON   (France)

ⁱ CENTRE RENÉ GAUDUCHEAU   (France)

^j INSTITUT CLAUDIUS REGAUD   (France)

^k Centre George Fra ois Leclerc   (France)

^l CENTRE ANTOINE LACASSAGNE   (France)

^m Paris   (France)

ⁿ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^o CENTRE LÉON BÉRARD   (France)

^p CENTRE VAL D AURELLE   (France)

^q CENTRE HENRI BECQUEREL   (France)

more..

Author keywords

Acute toxicity; Conformal therapy; Dose escalation; Dose volume histograms; Prostate cancer

Indexed keywords

ACUTE TOLERANCE; PROSTATE; RANDOMIZED TRIAL; SURGICAL STAGING;

RANDOM PROCESSES; RISK ASSESSMENT; TOXICITY; TUMORS;

PATIENT MONITORING;

ANDROGEN;

ACUTE TOXICITY; AGED; ARTICLE; CANCER GRADING; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SIZE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOGRAM; HUMAN; INFORMATION RETRIEVAL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION FIELD; RADIATION INJURY; RADIATION NECROSIS; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; STATISTICAL SIGNIFICANCE;

AGED; ANALYSIS OF VARIANCE; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL;

EID: 7444264681     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.05.033     Document Type: Article

References (42)

1. A. Jemal, T. Murray, A. Samuels Cancer statistics, 2003 CA Cancer J Clin 53 2003 5 26
2. L. Remontet, J. Esteve, A.M. Bouvier Cancer incidence and mortality in France over the period 19782000 Rev Epidemiol Sante Publique 51 2003 3 30
3. A.L. Zietman, J.J. Coen, K.C. Dallow The treatment of prostate cancer by conventional radiation therapy An analysis of long-term outcome Int J Radiat Oncol Biol Phys 32 1995 287 292
4. G.E. Hanks, K.L. Martz, J.J. Diamond The effect of dose on local control of prostate cancer Int J Radiat Oncol Biol Phys 15 1988 1299 1306
5. C.A. Lawton, M. Won, M.V. Pilepich Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate Analysis of RTOG studies 7506 and 7706 Int J Radiat Oncol Biol Phys 21 1991 935 939
6. C.A. Perez, G.E. Hanks, S.A. Leibel Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy Cancer 72 1993 3156 3173
7. H.M. Sandler 3-D conformal radiotherapy for prostate cancer. The University of Michigan experience Front Radiat Ther Oncol 29 1996 238 243
8. G.E. Hanks, A.L. Hanlon, T.E. Schultheiss Dose escalation with 3D conformal treatment Five year outcomes, treatment optimization, and future directions Int J Radiat Oncol Biol Phys 41 1998 501 510
9. A. Pollack, G.K. Zagars External beam radiotherapy dose response of prostate cancer Int J Radiat Oncol Biol Phys 39 1997 1011 1018
10. M.J. Zelefsky, S.A. Leibel, P.B. Gaudin Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer Int J Radiat Oncol Biol Phys 41 1998 491 500
11. P. Bey, C. Carrie, V. Beckendorf Dose escalation with 3D-CRT in prostate cancer French study of dose escalation with conformal 3D radiotherapy in prostate cancerpreliminary results Int J Radiat Oncol Biol Phys 48 2000 513 517
12. J.K. Ryu, K. Winter, J.M. Michalski Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy) Int J Radiat Oncol Biol Phys 54 2002 1036 1046
13. A. Pollack, G. Zagars, G. Starkhall Prostate cancer radiation dose response Final planned analysis of a phase III randomized trial [Abstract] Proc Am Soc Clin Oncol 21 2002 703
14. P.C. Albertesen, D.G. Fryback, B.E. Storer The impact of co-morbidity on life expectancy among men with localized prostate cancer J Urol 156 1996 127 132
15. UICC, Cancer IUA. TNM atlas. 4th ed. Springer; 1997.
16. A.W. Partin, M.W. Kattan, E.N. Subong Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer A multi-institutional update JAMA 277 1997 1445 1451
17. ICRU. ICRU Report 50: Prescribing, recording and reporting photon beam therapy. Bethesda, MD: International Commission on Radiation Units and Measurements; 1993.
18. ICRU. ICRU Report 62: Prescribing, recording and reporting photon beam therapy. (Supplement to ICRU report 50). Bethesda, MD; 1999.
19. P.J. Keall, J.V. Siebers, R. Jeraj The effect of dose calculation uncertainty on the evaluation of radiotherapy plans Med Phys 27 2000 478 484
20. Beckendorf V, Bachaud JM, Bey P et al. [Target-volume and critical-organ delineation for conformal radiotherapy of prostate cancer: Experience of French dose-escalation trials]. Cancer Radiother 2002;6:78-92s.
21. J.D. Cox, J. Stetz, T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
22. Wartelle M, Kramar A, Jan P. PIGAS: An interactive statistical database management system. Second international workshop on statistical database management. Los Altos, CA; 1983. p. 124-132.
23. A. van't Riet, A.C. Mak, M.A. Moerland A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation Application to the prostate Int J Radiat Oncol Biol Phys 37 1997 731 736
24. G. Madelis Quality assurance and uncertainty analysis in prostate conformal radiotherapy Med Phys 26 1999 2205
25. J.M. Michalski, J.A. Purdy, K. Winter Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406 Int J Radiat Oncol Biol Phys 46 2000 391 402
26. Pollack A, Hanlon A, Horwitz EM, et al. Radiation therapy dose escalation for prostate cancer: A rationale for IMRT. World J Urol 2003.
27. M.J. Zelefsky, Z. Fuks, M. Hunt High-dose intensity modulated radiation therapy for prostate cancer Early toxicity and biochemical outcome in 772 patients Int J Radiat Oncol Biol Phys 53 2002 1111 1116
28. F.E. Yang, F. Vaida, L. Ignacio Acute toxicity in radiotherapy of prostate cancer Results of a randomized study with and without beam's-eye view three-dimensional conformal therapy Radiat Oncol Investing 4 1996 231 238
29. R.H. Chou, R.B. Wilder, M. Ji Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy Int J Radiat Oncol Biol Phys 47 2000 115 119
30. J.J. Nuyttens, S. Milito, P.F. Rust Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer Radiother Oncol 64 2002 209 214
31. M.R. Storey, A. Pollack, G. Zagars Complications from radiotherapy dose escalation in prostate cancer Preliminary results of a randomized trial Int J Radiat Oncol Biol Phys 48 2000 635 642
32. J. Lebesque, P. Koper, A. Slot Acute and late GI and GU toxicity after prostate irradiation to doses of 68 Gy and 78 Gy; Result of a randomized trial Int J Radiat Oncol Biol Phys 57 2003 S152
33. A. Pollack, G.K. Zagars, G. Starkschall Conventional vs. conformal radiotherapy for prostate cancer Preliminary results of dosimetry and acute toxicity Int J Radiat Oncol Biol Phys 34 1996 555 564
34. P.C. O'Brien, C.I. Franklin, M.G. Poulsen Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis Longer term followup of a phase III trialTran-Tasman Radiation Oncology Group Int J Radiat Oncol Biol Phys 54 2002 442 449
35. D.M. Tait, A.E. Nahum, L.C. Meyer Acute toxicity in pelvic radiotherapy A randomized trial of conformal versus conventional treatment Radiother Oncol 42 1997 121 136
36. A.V. D'Amico, R. Whittington, I. Kaplan Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV Int J Radiat Oncol Biol Phys 39 1997 335 340
37. M. Roach 3rd, C. Marquez, H.S. Yuo Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 28 1994 33 37
38. L. Kestin, N. Goldstein, F. Vicini Treatment of prostate cancer with radiotherapy Should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys 54 2002 686 697
39. Salomon L, Porcher R, Anastasiadis AG, et al. Introducing a prognostic score for pretherapeutic assessment of seminal vesicle invasion in patients with clinically localized prostate cancer. Radiother Oncol 2003; in press.
40. M.J. Zelefsky, A. Harrison Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer Reducing the potential morbidity of therapy Urology 49 1997 38 45
41. P.A. Kupelian, J.C. Buchsbaum, C.A. Reddy Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason or = 6, and pretreatment prostate-specific antigen or = 10) Int J Radiat Oncol Biol Phys 50 2001 621 625
42. Z. Symon, K.A. Griffith, P.W. McLaughlin Dose escalation for localized prostate cancer Substantial benefit observed with 3D conformal therapy Int J Radiat Oncol Biol Phys 57 2003 384 390